Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01039519 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)
A Phase 2 study, sponsored by Synta Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT01039519: Completed Phase 2 study, sponsored by Synta Pharmaceuticals.
NCT01039519 is a Phase 2 study that has completed, run by Synta Pharmaceuticals. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01039519, a Phase 2 study, has completed, sponsored by Synta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if STA-9090 is effective in the treatment of patients with metastatic and/or unresectable GIST.
Interventions
- DRUG Ganetespib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01039519
The ClinicalTrials.gov registry entry for NCT01039519 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Synta Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ganetespib is the first listed.
NCT01039519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01039519 about?
NCT01039519 is a clinical study titled "A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)". The purpose of this study is to determine if STA-9090 is effective in the treatment of patients with metastatic and/or unresectable GIST.
What is the current status of trial NCT01039519?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2010-01. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01039519?
The interventions under investigation include: Ganetespib (DRUG).
Who is sponsoring clinical trial NCT01039519?
This trial is sponsored by Synta Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.